Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.30 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.30 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.30 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21624374 | 0.89 | — | — | |
| SCHEMBL21624404 | 0.83 | — | — | |
| SCHEMBL21624388 | 0.83 | — | — | |
| SCHEMBL23647728 | 0.81 | — | — | |
| SCHEMBL21624302 | 0.79 | MEN1 (0.30) | — | |
| SCHEMBL21624347 | 0.79 | GRIN2B (0.32) | — | |
| SCHEMBL21624376 | 0.79 | HSD11B1 (0.32) | MAPK1 | |
| SCHEMBL21624381 | 0.79 | — | — | |
| SCHEMBL23648153 | 0.78 | — | — | |
| SCHEMBL23647727 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2021-06-03 | — | — | US | disclosed |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | Grünenthal GmbH (DE) | 2021-04-20 | — | — | US | disclosed |
| WO-2020016452-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | Grünenthal GmbH (DE) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163491-A1 | FURTHER SUBSTITUTED TRIAZOLO QUINOXALINE DERIVATIVES | NR3C1, GRK5, NR3C2 | MAPK1 821/4885MAP2K4 1986/4885MAPKAPK2 982/4885 |
| US-10981918-B2 | Further substituted triazolo quinoxaline derivatives | NR3C1, GRK5, NR3C2 | MAPK1 821/4885MAP2K4 1986/4885MAPKAPK2 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.